Equities Analysts Issue Forecasts for APLS Q3 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Investment analysts at Wedbush issued their Q3 2026 EPS estimates for Apellis Pharmaceuticals in a report issued on Wednesday, April 16th. Wedbush analyst L. Chico forecasts that the company will post earnings per share of ($0.22) for the quarter. Wedbush currently has a “Neutral” rating and a $29.00 target price on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. Wedbush also issued estimates for Apellis Pharmaceuticals’ Q4 2026 earnings at ($0.14) EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company had revenue of $212.50 million during the quarter, compared to analysts’ expectations of $197.92 million. During the same period last year, the business posted ($0.73) earnings per share. The firm’s revenue was up 45.2% compared to the same quarter last year.

APLS has been the subject of several other reports. JPMorgan Chase & Co. upped their target price on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 4th. The Goldman Sachs Group reduced their target price on Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $57.00 price target on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. Royal Bank of Canada reduced their price objective on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating for the company in a research note on Monday, March 3rd. Finally, Scotiabank lifted their target price on shares of Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a “sector perform” rating in a research note on Wednesday, April 2nd. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $45.59.

Apellis Pharmaceuticals Stock Performance

NASDAQ APLS opened at $18.20 on Thursday. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -8.97 and a beta of 0.85. The stock has a 50-day moving average of $23.93 and a 200 day moving average of $28.07. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals has a twelve month low of $17.49 and a twelve month high of $50.98.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC boosted its position in shares of Apellis Pharmaceuticals by 2,707.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock worth $25,000 after purchasing an additional 758 shares during the period. Signaturefd LLC grew its stake in shares of Apellis Pharmaceuticals by 357.2% in the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock valued at $37,000 after buying an additional 918 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Apellis Pharmaceuticals in the fourth quarter valued at $83,000. US Bancorp DE raised its holdings in shares of Apellis Pharmaceuticals by 70.0% in the 4th quarter. US Bancorp DE now owns 3,223 shares of the company’s stock valued at $103,000 after buying an additional 1,327 shares during the period. Finally, Covestor Ltd lifted its stake in Apellis Pharmaceuticals by 1,819.2% during the 4th quarter. Covestor Ltd now owns 3,992 shares of the company’s stock worth $127,000 after acquiring an additional 3,784 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 3,088 shares of Apellis Pharmaceuticals stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total value of $93,967.84. Following the sale, the chief financial officer now owns 129,211 shares in the company, valued at $3,931,890.73. The trade was a 2.33 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO James George Chopas sold 1,096 shares of the stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total value of $33,351.28. Following the transaction, the chief accounting officer now owns 48,138 shares of the company’s stock, valued at approximately $1,464,839.34. This represents a 2.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 36,011 shares of company stock worth $1,059,969 in the last ninety days. 6.80% of the stock is owned by insiders.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).